gvtcx

Commercial Kit for screening for hereditary tyrosinemia type 1 (HT1)

NHS England Published 27 Aug 2025 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£1,677,290
Statuscomplete
Category (CPV) 33696200
Deadline31 Mar 2025
Contract start1 Apr 2025
Contract end31 Mar 2027
Procedureselective
SME suitableNo
OCIDocds-b5fd17-05c35d6c-e5e5-4618-9fc5-a047424e85cf

Award

SupplierValueDateStatus
Revvity (UK) Limited £1,677,290 30 Mar 2025 active

description

Newborn Blood Spot screening (NBS) is a national programme offered to all babies born in the UK, and it currently screens for 9 rare but potentially lethal conditions. The blood spot screening sample is taken from the baby's heel collected on a filter paper dried blood spot (DBS) card. The blood sample is analysed by one of 13 newborn screening laboratories in England

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
27 Aug 2025 Award (award) · b799e693-eab3-4435-a855-4f8f34619110-860909

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.